Direct thrombin inhibitor prevents delayed graft function in a porcine model of renal transplantation

Transplantation

Volumn 87, Issue 11, 2009, Pages 1636-1644

  Giraud, Sebastien ^a   Thuillier, Raphael ^a   Belliard, Aude ^a,c   Hebrard, William ^d   Nadeau, Cédric ^f   Milin, Serge ^g   Goujon, Jean Michel ^a,h   Manguy, Emilie ^a   Mauco, Gérard ^a,b,e   Hauet, Thierry ^a,b,e   MacChi, Laurent ^a,f,i  

^a INSERM   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CEMAGREF   (France)

^e POITIERS UNIVERSITY HOSPITAL   (France)

^f Service d'Hmatologie et Oncologie Biologique   (France)

^g Service de Chirurgie Viscérale et Endocrinienne   (France)

^h Service d'Anatomie Pathologique   (France)

ⁱ ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Direct thrombin inhibitor; Graft function; Ischemia Reperfusion Injury; Kidney preservation; Pig model transplantation

Indexed keywords

MELAGATRAN; THROMBIN ANTITHROMBIN COMPLEX; THROMBIN INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; DELAYED GRAFT FUNCTION; DRUG MECHANISM; INFLAMMATION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWINE; THROMBOELASTOGRAPHY;

ANIMALS; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; BRAIN DEATH; CELL SURVIVAL; CREATININE; HEART ARREST; KIDNEY TRANSPLANTATION; MALE; MITOCHONDRIA; MODELS, ANIMAL; PARTIAL THROMBOPLASTIN TIME; RENAL CIRCULATION; REPERFUSION INJURY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SWINE; THROMBIN; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 67649576895     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a5b154     Document Type: Article

References (36)

1. Strukova S. Blood coagulation-dependent inflammation. Coagulationdependent inflammation and inflammation-dependent thrombosis. Front Biosci 2006; 11: 59.
2. Farivar AS, Delgado MF, McCourtie AS, et al. Crosstalk between thrombosis and inflammation in lung reperfusion injury. Ann Thorac Surg 2006; 81: 1061.
3. Brook NR, Nicholson ML. Kidney transplantation from non heartbeating donors. Surgeon 2003; 1: 311.
4. Gerstenkorn C. Non-heart-beating donors: Renewed source of organs for renal transplantation during the twenty-first century. World J Surg2003; 27: 489.
5. Kootstra G. The asystolic, or non-heartbeating, donor. Transplantation1997; 63: 917.
6. Rudich SM, Kaplan B, Magee JC, et al. Renal transplantations performed using non-heart-beating organ donors: Going back to the future? Transplantation 2002; 74: 1715.
7. Asher J, Wilson C, Gok M, et al. Factors predicting duration of delayed graft function in non-heart-beating donor kidney transplantation. Transplant Proc 2005; 37: 348.
8. Keizer KM, de Fijter JW, Haase-Kromwijk BJ, et al. Non-heart-beating donor kidneys in the Netherlands: Allocation and outcome of transplantation. Transplantation 2005; 79: 1195.
9. Brook NR, White SA, Waller JR, et al. Non-heart beating donor kidneys with delayed graft function have superior graft survival compared with conventional heart-beating donor kidneys that develop delayed graft function. Am J Transplant 2003; 3: 614.
10. Koo DD, Welsh KI, Roake JA, et al. Ischemia/reperfusion injury in human kidney transplantation: An immunohistochemical analysis of changes after reperfusion. Am J Pathol 1998; 153: 557.
11. Chambers RC, Laurent GJ. Coagulation cascade proteases and tissue fibrosis. Biochem Soc Trans 2002; 30: 194.
12. Yan SF, Mackman N, Kisiel W, et al. Hypoxia/hypoxemia-induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 2029.
13. Cassie S, Masterson MF, Polukoshko A, et al. Ischemia/reperfusion induces the recruitment of leukocytes from whole blood under flow conditions. Free Radic Biol Med 2004; 36: 1102.
14. Dragun D, Hoff U, Park JK, et al. Ischemia-reperfusion injury in renal transplantation is independent of the immunologic background. Kidney Int 2000; 58: 2166.
15. Del Prete G, De Carli M, Lammel RM, et al. Th1 and Th2 T-helper cells exert opposite regulatory effects on procoagulant activity and tissue factor production by human monocytes. Blood 1995; 86: 250.
16. Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 1994; 91: 8767.
17. Colognato R, Slupsky JR, Jendrach M, et al. Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells. Blood 2003; 102: 2645.
18. He CJ, Peraldi MN, Adida C, et al. Thrombin signal transduction mechanisms in human glomerular epithelial cells. J Cell Physiol 1992; 150: 475.
19. Hertig A, Rondeau E. Role of the coagulation/fibrinolysis system in fibrin-associated glomerular injury. J Am Soc Nephrol 2004; 15: 844.
20. Erlich JH, Boyle EM, Labriola J, et al. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation.AmJ Pathol 2000; 157: 1849.
21. Holschermann H, Bohle RM, Schmidt H, et al. Hirudin reduces tissue factor expression and attenuates graft arteriosclerosis in rat cardiac allografts. Circulation 2000; 102: 357.
22. Eriksson M, Larsson A, Saldeen T, et al. Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig. Thromb Haemost 1998; 80: 1022.
23. Mattsson C, Sarich TC, Carlsson SC. Mechanism of action of the oral direct thrombin inhibitor ximelagatran. Semin Vasc Med 2005; 5: 235.
24. Sarich TC, Osende JI, Eriksson UG, et al. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis. J Thromb Haemost 2003; 1: 999.
25. Belliard A, Mauco G, Bonnet ML, et al. Melagatran prevent tissue factor expression in human platelet-monocyte heterotypic complexes. Cell Mol Biol 2008; 54: OL1077.
26. Jayle C, Milinkevitch S, Favreau F, et al. Protective role of selectin ligand inhibition in a large animal model of kidney ischemia-reperfusion injury. Kidney Int 2006; 69: 1749.
27. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant2008; 8: 753.
28. Yuan JS, Reed A, Chen F, et al. Statistical analysis of real-time PCR data. BMC Bioinformatics 2006; 7: 85.
29. Sorensen B, Ingerslev J. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. Thromb Haemost 2006; 96: 446.
30. Cozzi E, Simioni P, Boldrin M, et al. Alterations in the coagulation profile in renal pig-to-monkey xenotransplantation. Am J Transplant2004; 4: 335.
31. Mizutani A, Okajima K, Uchiba M, et al. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood2003; 101: 3029.
32. Sevastos J, Kennedy SE, Davis DR, et al. Tissue factor deficiency and PAR-1 deficiency are protective against renal ischemia reperfusion injury. Blood 2007; 109: 577.
33. Poschel KA, Bucha E, Esslinger HU, et al. Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure. Kidney Int 2000; 58: 2478.
34. Humphreys BD, Valerius MT, Kobayashi A, et al. Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell 2008; 2: 284.
35. Gok MA, Shenton BK, Peaston R, et al. Improving the quality of kidneys from non-heart-beating donors, using streptokinase: An animal model. Transplantation 2002; 73: 1869.
36. Yamauchi J, Schramm R, Richter S, et al. Improvement of microvascular graft equilibration and preservation in non-heart-beating donors by warm preflush with streptokinase. Transplantation 2003; 75: 449.